Abstract Details

Title Safety and efficacy of IV cladribine versus alemtuzumab in aggressive multiple sclerosis: a retrospective cohort study

Topic Multiple Sclerosis

Presentation(s) P1 - (-)

Poster/Presentation
Number 368

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Gauruv Bose, MD (The University of Ottawa and Ottawa Hospital Research Institute) PRESENTER	Dr. Bose has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Bose has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Bose has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva Pharmaceuticals. The institution of Dr. Bose has received research support from Multiple Sclerosis Society of Canada.
	No disclosure on file
Carolina A. Rush, MD	Dr. Rush has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche . Dr. Rush has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen . Dr. Rush has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen . Dr. Rush has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi . Dr. Rush has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi . Dr. Rush has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pendopharm . Dr. Rush has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi .
	No disclosure on file
	No disclosure on file